Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News Meet us in Munich: AGAH Annual Meeting 26 – 27 April 2018 Regorafenib: first in human as eye drops 3rd GBHI conference – all speakers confirmed 1st GBHI-Conference – Conference Report now available 3rd GBHI conference – program is online Who is a healthy subject? Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Biopharmaceutical Clinical study Subcontractor qualification Informed Consent Procedure MMM Legal representative Ovulation inhibition Absorption windows Phase IIa trials Cardiovascular surveillance Bioavailability Steady state SOP based Creativity Sore throat Endpoint Absorption Xerostomia Immunogenicity In vitro in vivo correlation Expert Oncological patients Axis DFI Sample size estimation Quality FIM Inspection Design development Common cold Lung Ophthalmology Clinical pharmacology unit Contraception SocraTec C&S SDV Database MDI Oncologic network Consultancy CDM Protocol Patients Clinical development program Non interventional Project Management Pulse oximetry plethysmography Centralised procedure Data Management Plan Source Data Verification Data Validation Plan Protocol development OTC GCP Statistical programming Referral system Ophthalmologist Allergy Postmenopausal women IMPD Oncology Safety Pharmacokinetics Inhalatives Pharmacology Glaucoma Phase II Dose linearity Central surveillance system Pilot study IVIVC SAS Dermal irritation First in human Hormone replacement therapy Statistical services Hypothalamic CRA Patient recruitment Anaesthesiologist Phase IV Patch Auditing Training Phase III Drug Drug Interaction US CFR 21 Part 11 Early phase Quality Assurance Cough Clinical trials Phase IIb trials Post authorisation CRF Biopharmaceutics Children Statistical Analysis Plan Feasibility Intensive assessment station Quality Management System FDA HPA axis Gynaecological trials Good Clinical Practice IB Standardisation Competence Uveitis ICF Legal Information MCID CRO Pharmacodynamic studies DPI TTS Investigators brochure Paediatricians Sensitisation trials Patch adhesion Efficacy Biometrics NIS Drug Food Interaction AGAH GLP Phase I Unit Rhine Main area DDI Adrenocortical Phase I IEC PAES Pharmacokintetics CDASH Slit lamp microscopy Local tolerability Monitoring Dry eye Thuringia DUS Life cycle management US FDA Clinical Monitoring Degeneration Pragmatism Female adolescents GCP training Pituitary HRT Edema Audit Scientific advice Data management Recruitment rates Spacious archive Copyright Eye disease CDSIC Network Bioequivalence Charcoal Transdermal therapeutic system Highly variable drugs Standard operating procedure Dry powder inhaler ADAM WinNonlin Elpro Ophthalmological trials Ocular tolerability COPD EMA Healthy subjects PASS Product development ANVISA Sequential designs Biosimilars Scientific expertise HTA CDISC Authorities Experience Asthma Macular Metered dose inhaler  

All fine on front page